91Ö±²¥

All publications

Journal articles

• Keetharuth AD, Gould R, McDermott C, Thompson B, Rawlinson C, Bradburn M, Bursnall M, Kumar P, Turton E, Tappenden P , White D et al (2024) . European Journal of Neurology.
• Wheaton L, Poad H, Tappenden P & Bujkiewicz S (2023) . Value in Health, 26(12), S425-S425.
• Lister J, Paisley S, Tappenden P & Carroll C (2023) . Value in Health, 26(12), S375-S375.
• Lister J, Paisley S, Tappenden P & Carroll C (2023) . Value in Health, 26(12), S174-S175.
• Needham KJ, Tappenden P, Gillespie D & Whyte S (2023) . Journal of Thoracic Oncology, 18(11), S134-S134.
• Umemneku-Chikere CM, Wheaton L, Poad H, Ray D, Andrade IC, Khan S, Tappenden P, Abrams KR, Owen RK & Bujkiewicz S (2023) . Journal of Clinical Epidemiology, 164, 96-103.
• Tappenden P, Navega Biz A, Hernández Alava M, Sasso A, Sutton L, Ennis K, Elliott R & Wildman M (2023) . International Journal of Technology Assessment in Health Care, 39(1).
• Murphy P, Glynn D, Dias S, Hodgson R, Claxton L, Beresford L, Cooper K, Tappenden P, Ennis K, Grosso A , Wright K et al (2022) . Health Technology Assessment, 25(76), 1-228.
• Burt RK, Tappenden P, Balabanov R, Han X, Quigley K, Snowden JA & Sharrack B (2021) . Frontiers in Neurology, 12.
• Srivastava T, Latimer NR & Tappenden P (2021) . PharmacoEconomics.
• Burt RK, Tappenden P, Han X, Quigley K, Arnautovic I, Sharrack B, Snowden JA & Hartung D (2020) . Multiple Sclerosis and Related Disorders, 45.
• Jin H, Tappenden P, Robinson S, Achilla E, Aceituno D & Byford S (2020) . PLOS ONE, 15(7).
• Jin H, Tappenden P, MacCabe JH, Robinson S & Byford S (2020) . JAMA network open, 3(5).
• Jin H, Tappenden P, Robinson S, Achilla E, MacCabe JH, Aceituno D & Byford S (2020) . PharmacoEconomics.
• Tappenden P, Wang Y, Sharrack B, Burman J, Kazmi M, Saccardi R, Bermejo I, Harvey R, Badoglio M, Farge D & Snowden JA (2020) . Bone Marrow Transplantation, 55(7), 1473-1475.
• Alshreef A, Latimer N, Tappenden P, Wong R, Hughes D, Fotheringham J & Dixon S (2019) . Medical Decision Making.
• Tappenden P & Caro JJ (2019) . PharmacoEconomics, 37(11), 1303-1304.
• Harnan S, Tappenden P, Cooper K, Stevens J, Bessey A, Rafia R, Ward S, Wong R, Stein RC & Brown J (2019) . Health Technology Assessment, 23(30).
• Tappenden P, Carroll C, Hamilton J, Kaltenthaler E, Wong R, Wadsley J, Moss L & Balasubramanian S (2019) . Health Technology Assessment, 23(8), 1-144.
• Tappenden P, Carroll C, Stevens J, Simpson E, Thokala P, Wong R, Wright J & Auer R (2019) . PharmacoEconomics, 37(1), 7-18.
• Tappenden P, Simpson E, Hamilton J, Pollard D, Clowes M, Kaltenthaler E, Meiklejohn D & Morley N (2018) . PharmacoEconomics.
• Bermejo I, Tappenden P & Youn JH (2017) . PharmacoEconomics.
• Tappenden P, Carroll C, Stevens JW, Rawdin A, Grimm S, Clowes M, Kaltenthaler E, Ingram JR, Collier F & Ghazavi M (2017) . PharmacoEconomics, 35(8), 805-815.
• Bermejo I, Tappenden P & Youn JH (2017) . Pharmacoeconomics.
• Uttley L, Whyte S, Gomersall T, Ren S, Wong R, Chambers D & Tappenden P (2017) . PharmacoEconomics, 35(7), 717-726.
• Tappenden P, Sadler S & Wildman M (2017) . PharmacoEconomics, 35(6).
• Carroll C, Kaltenthaler E, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M, Tappenden P & Woolacott N (2017) . Value in Health, 20(6), 785-791.
• Atkin W, Brenner A, Martin J, Wooldrage K, Shah U, Lucas F, Greliak P, Pack K, Kralj-Hans I, Thomson A , Perera S et al (2017) . Health Technology Assessment, 21(25), 1-536.
• Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, Durrington P, Qureshi N & Wierzbicki AS (2017) . PharmacoEconomics, 35(5), 537-547.
• Harnan SE, Essat M, Gomersall T, Tappenden P, Pavord I, Everard M & Lawson R (2017) . Clinical and Experimental Allergy, 47(3), 410-429.
• Tappenden P, Harnan S, Ren S, Thokala P, Wong R, Mukuria C, Green C, Pledge S & Tidy J (2017) . PharmacoEconomics, 35(1), 97-109.
• Kaltenthaler E, Carroll C, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M, Tappenden P & Woolacott N (2016) . PharmacoEconomics - Open.
• Tappenden P, Ren S, Archer R, Harvey R, Martyn-St James M, Basarir H, Stevens J, Lobo A & Hoque S (2016) . PharmacoEconomics, 34(10), 1023-1038.
• Thokala P, Simpson E, Tappenden P, Stevens J, Dickinson K, Ryder S & Harrison P (2016) . PharmacoEconomics, 34(8), 741-750.
• Sadler S, Wildman M & Tappenden P (2016) . Journal of Cystic Fibrosis, 15, S119-S120.
• Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, Stevens J, Carroll C, Cantrell A, Lobo A & Hoque S (2016) . Health Technology Assessment, 20(39), 1-326.
• Kaltenthaler E, Carroll C, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M, Tappenden P & Woolacott N (2016) . Health Technology Assessment, 20(26), 1-48.
• Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, Durrington P, Qureshi N & Wierzbicki AS (2016) . PharmacoEconomics, 35(5), 537-547.
• Gomersal T, Harnan S, Essat M, Tappenden P, Wong R, Lawson R, Pavord I & Everard ML (2016) . Pediatric Pulmonology, 51(3), 316-328.
• Essat M, Tappenden P, Ren S, Bessey A, Archer R, Wong R, Lobo A & Hoque S (2016) . PharmacoEconomics, 34(3), 245-257.
• Essat M, Harnan S, Gomersall T, Tappenden P, Wong R, Pavord I, Lawson R & Everard M (2016) . European Respiratory Society, 47(3), 751-768.
• Asaria M, Griffin S, Cookson R, Whyte S & Tappenden P (2015) . Health Econ, 24(6), 742-754.
• Latimer NR, Carroll C, Wong R, Tappenden P, Venning MC & Luqmani R (2014) . PharmacoEconomics, 32(12), 1171-1183.
• Tappenden P & Chilcott J (2014) . Value in Health, 17(7), A585-A585.
• Uttley L & Tappenden P (2014) . Current Opinion in Pulmonary Medicine, 20(6), 607-612.
• Tappenden P & Chilcott JB (2014) . Pharmacoeconomics, 32(10), 967-979.
• Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad ED, Buyse M & Taylor RS (2014) . International Journal of Technology Assessment in Health Care, 30(3), 312-324.
• Kaltenthaler E, Essat M, Tappenden P & Paisley S (2014) . International Journal of Technology Assessment in Health Care, 30(3), 333-340.
• Tappenden P, Harnan S, Uttley L, Mildred M, Walshaw M, Taylor C & Brownlee K (2014) . PHARMACOECONOMICS, 32(2), 159-172.
• Stevenson M, Tappenden P & Squires H (2014) . International Journal of Systems Science, 45(1), 60-68.
• Lord J, Willis S, Eatock J, Tappenden P, Trapero-Bertran M, Miners A, Crossan C, Westby M, Anagnostou A, Taylor S , Mavranezouli I et al (2013) . Health Technol Assess, 17(58), v-192.
• Tappenden P, Harnan S, Uttley L, Mildred M, Carroll C & Cantrell A (2013) . Health Technol Assess, 17(56), v-181.
• Uttley L, Harnan S, Cantrell A, Taylor C, Walshaw M, Brownlee K & Tappenden P (2013) . Eur Respir Rev, 22(130), 476-486.
• Asaria M, Griffin S, Cookson R, Tappenden P & Whyte S (2013) . VALUE IN HEALTH, 16(7), A426-A426.
• Kaltenthaler E, Tappenden P & Paisley S (2013) . Value in Health, 16(5), 830-836.
• Simpson EL, Fitzgerald P, Evans P, Tappenden P, Kalita N, Reckless JPD & Bakhai A (2013) . Pharmacoeconomics, 31(4), 269-275.
• Hoyle M, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, Tappenden P & Hyde C (2013) . Health Technol Assess, 17(14), 1-237.
• Sharp L, Tilson L, Whyte S, Ceilleachair AO, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M & Comber H (2013) . BMC Health Serv Res, 13, 105.
• Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A & Cantrell A (2013) . BMJ Open, 3(11), e003573.
• Tappenden P, Chilcott J, Brennan A, Squires H, Glynne-Jones R & Tappenden J (2013) . Value in Health.
• Tappenden P, Chilcott J, Brennan A, Squires H & Stevenson M (2012) . Value Health, 15(8), 1127-1136.
• Tappenden P, Campbell F, Rawdin A, Wong R & Kalita N (2012) . Health Technol Assess, 16(20), 1-72.
• Sharp L, Tilson L, Whyte S, O'Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M & Comber H (2012) . Br J Cancer, 106(5), 805-816.
• Shabaruddin FH, Elliott RA, Tappenden P & Payne K (2012) Assessing the costs and benefits of a pharmacogenetic test to reduce the incidence of adverse events. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 21(1), 118-118.
• Delea TE, Tappenden P, Sofrygin O, Browning D, Amonkar MM, Karnon J, Walker MD & Cameron D (2012) . Eur J Health Econ, 13(5), 589-603.
• Tilson L, Sharp L, Usher C, Walsh C, Whyte S, O'Ceilleachair A, Stuart C, Mehigan B, Kennedy MJ, Tappenden P , Chilcott J et al (2012) . European Journal of Health Economics, 13(4), 511-524.
• Shabaruddin FH, Elliott RA, Tappenden P & Payne K (2011) . VALUE IN HEALTH, 14(7), A251-A252.
• Shabaruddin FH, Elliott RA, Tappenden P & Payne K (2011) . VALUE IN HEALTH, 14(7), A252-A252.
• Squires H, Tappenden P, Cooper K, Carroll C, Logan R & Hind D (2011) . Clinical Therapeutics, 33(9), 1289-1305.
• Whyte S, Walsh C & Chilcott J (2011) . Medical Decision Making, 31(4), 625-641.
• Jackson RJ, Cooper KL, Tappenden P, Rees A, Simpson EL, Read RC & Nicholson KG (2011) . J Infect, 62(1), 14-25.
• Papaioannou D, Cooper KL, Carroll C, Hind D, Squires H, Tappenden P & Logan RF (2011) . Colorectal Dis, 13(10), 1085-1099.
• Bending MW, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J & Tappenden J (2010) . Int J Technol Assess Health Care, 26(4), 362-369.
• Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D & Tappenden P (2010) . Health Technol Assess, 14(32), 1-206.
• Sofrygin O, Delea TE, Tappenden P, Karnon J, Browning D, Amonkar M, Lykopoulos K & Cameron DA (2010) . JOURNAL OF CLINICAL ONCOLOGY, 28(15).
• Carroll C, Cooper K, Papaioannou D, Hind D, Pilgrim H & Tappenden P (2010) . CLIN THER, 32(5), 789-803.
• Chilcott J, Tappenden P, Rawdin A, Johnson M, Kaltenthaler E, Paisley S, Papaioannou D & Shippam A (2010) . Health Technol Assess, 14(25), iii-107.
• Oakley JE, Brennan A, Tappenden P & Chilcott J (2010) . J Health Econ, 29(3), 468-477.
• Carroll C, Cooper K, Papaioannou D, Hind D, Tappenden P, Pilgrim H & Booth A (2010) . Aliment Pharmacol Ther, 31(7), 708-718.
• Bending MW, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J & Tappenden J (2010) . International Journal of Technology Assessment in Health Care, 26(4), 362-369.
• McCabe C, Chilcott J, Claxton K, Tappenden P, Cooper C, Roberts J, Cooper N & Abrams K (2010) . BMJ, 340, c1786.
• Madan J, Rawdin A, Stevenson M & Tappenden P (2010) . Value Health, 13(2), 215-221.
• Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL, Kozak T, Farge-Bancel D, Madan J, Rafia R , Akehurst R et al (2010) . Bone Marrow Transplant, 45(6), 1014-1021.
• Sharp L, Tilson L, Whyte S, O'Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Comber H & Barry M (2009) COST-EFFECTIVENESS OF A POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAMME IN IRELAND. VALUE HEALTH, 12(7), A280-A280.
• Pilgrim H, Tappenden P, Chilcott J, Bending M, Trueman P, Shorthouse A & Tappenden J (2009) . J OPER RES SOC, 60(10), 1305-1314.
• Tappenden P, Chilcott J, Brennan A & Pilgrim H (2009) . Int J Technol Assess Health Care, 25(4), 470-478.
• Whyte S, Walsh C, Sharp L, O'Ceilleachair A, Tilson L, Usher C, Chilcott J, Tappenden P, Staines A, Comber H & Barry M (2009) . Value in Health, 12(7), A395-A395.
• Hind D, Tappenden P, Peters J & Kenjegalieva K (2009) . Health Technol Assess, 13 Suppl 2, 9-13.
• Delea T, Sofrygin O, Tappenden P, Browning D, Amonkar MM, Karnon J & Lykopoulos K (2009) COST-EFFECTIVENESS (CE) ANALYSIS OF ERBB2-TARGETED THERAPIES IN WOMEN WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+METASTATIC BREAST CANCER (MBC) AND LIMITED EXPOSURE TO PRIOR CHEMOTHERAPY (CT). VALUE HEALTH, 12(3), A49-A49.
• Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R & Nicholson K (2009) . Health Technol Assess, 13(11), iii-246.
• Tappenden P, McCabe C, Chilcott J, Simpson E, Nixon R, Madan J, Fisk JD & Brown M (2009) . Value Health, 12(5), 657-665.
• Kerner JF, Cazap E, Yach D, Pierotti MA, Daidone MG, De Blasio P, Geary P, Schacter B, Sant M, Habbema JDF , Sankaranarayanan R et al (2009) . Tumori, 95(5), 610-622.
• Pickin M, Cooper CL, Chater T, O'Hagan A, Abrams KR, Cooper NJ, Boggild M, Palace J, Ebers G, Chilcott JB , Tappenden P et al (2009) . BMC Neurol, 9, 1.
• Kaltenthaler E, Tappenden P, Booth A & Akehurst R (2008) . Health Policy, 87(3), 389-400.
• DeLea T, Tappenden P, Sofrygin O, Karnon J, Amonkar M, Browning D, Rudge HJ & Walker MD (2008) Cost-effectiveness (CE) of lapatinib plus capecitabine (L+C) in women with HER2+ metastatic breast cancer (MBC) who received prior therapy with trastuzumab (TZ) based on updated survival data from EGF100151.. J Clin Oncol, 26(15_suppl), 6559.
• DeLea T, Tappenden P, Sofrygin O, Karnon J, Amonkar M, Browning D, Rudge HJ & Walker MD (2008) . JOURNAL OF CLINICAL ONCOLOGY, 26(15).
• Sofrygin O, Delea T, Tappenden P, Karnon J, Amonkar MM & Walker M (2008) Validity of proportional hazards (PH) Weibull models for analyzing progression free survival (PFS) and overall survival (OS) in patients with trastuzumab (TZ)-refractory ERBB2+(HER2+) metastatic breast cancer (MBC) receiving lapatinib plus capecitabine (L+C) versus capecitabine only (C-only). VALUE HEALTH, 11(3), A57-A57.
• Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P & Ryan A (2008) . Health Technol Assess, 12(15), iii-162.
• Karnon J, McIntosh A, Dean J, Bath P, Hutchinson A, Oakley J, Thomas N, Pratt P, Freeman-Parry L, Karsh B-T , Gandhi T et al (2008) . J Health Serv Res Policy, 13(2), 85-91.
• Garthwaite PH, Chilcott JB, Jenkinson DJ & Tappenden P (2008) . Int J Technol Assess Health Care, 24(3), 350-357.
• Parkin DM, Tappenden P, Olsen AH, Patnick J & Sasieni P (2008) . J Med Screen, 15(4), 163-174.
• Karnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J & Madan J (2007) A review and critique of modelling in prioritising and designing screening programmes.. Health technology assessment (Winchester, England), 11(52).
• Karnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J & Madan J (2007) A review and critique of modelling in prioritising and designing screening programmes. HEALTH TECHNOL ASSES, 11(52), 1-+.
• Tappenden P, Jones R, Paisley S & Carroll C (2007) . Eur J Cancer, 43(17), 2487-2494.
• Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H & Karnon J (2007) . Gut, 56(5), 677-684.
• Karnon J, McIntosh A, Dean J, Bath P, Hutchinson A, Oakley J, Thomas N, Pratt P, Freeman-Parry L, Karsh BT , Gandhi T et al (2007) . SAFETY SCI, 45(4), 523-539.
• Tappenden P, Jones R, Paisley S & Carroll C (2007) Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.. Health technology assessment (Winchester, England), 11(12).
• Tappenden P, Jones R, Paisley S & Carroll C (2007) Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.. Health technology assessment (Winchester, England), 11(12).
• Tappenden P, Jones R, Paisley S & Carroll C (2007) . Health Technol Assess, 11(12), 1-iv.
• Karnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J & Madan J (2007) A review and critique of modelling in prioritising and designing screening programmes.. Health technology assessment (Winchester, England), 11(52).
• Tappenden P, Brazier J, Ratcliffe J & Chilcott J (2007) . Pharmacoeconomics, 25(8), 685-693.
• Eggington S, Tappenden P, Pandor A, Paisley S, Saunders M, Seymour M, Sutcliffe P & Chilcott J (2006) . Br J Cancer, 95(9), 1195-1201.
• Pandor A, Eggington S, Paisley S, Tappenden P & Sutcliffe P (2006) The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.. Health technology assessment (Winchester, England), 10(41).
• Pandor A, Eggington S, Paisley S, Tappenden P & Sutcliffe P (2006) . Health Technol Assess, 10(41), iii-185.
• Tappenden P, Chilcott J, Ward S, Eggington S, Hind D & Hummel S (2006) . Eur J Cancer, 42(17), 2867-2875.
• Chilcott J, Tappenden P, Lloyd Jones M, Wight J, Forman K, Wray J & Beverley C (2004) . BJOG, 111(9), 903-907.
• Jones ML, Wray J, Wight J, Chilcott J, Forman K, Tappenden P & Beverley C (2004) . BJOG, 111(9), 892-902.
• Tappenden P, Chilcott JB, Eggington S, Oakley J & McCabe C (2004) . Health Technol Assess, 8(27), iii-78.
• Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper NJ, Abrams K, Claxton K, Miller DH & Cost Effectiveness of Multiple Sclerosis Therapies Study Group (2003) . BMJ, 326(7388), 522.
• Chilcott J, Brennan A, Booth A, Karnon J & Tappenden P (2003) The role of modelling in prioritising and planning clinical trials.. Health technology assessment (Winchester, England), 7(23).
• Chilcott J, Lloyd Jones M, Wight J, Forman K, Wray J, Beverley C & Tappenden P (2003) . Health Technol Assess, 7(4), iii-62.
• Richards RG, Sampson FC, Beard SM & Tappenden P (2002) . Health Technology Assessment, 6(10).
• Chilcott J, Tappenden P, Jones ML & Wight JP (2001) . Clin Ther, 23(11), 1792-1823.
• Chilcott J, Wight J, Jones ML & Tappenden P (2001) . Health Technology Assessment, 5(19).
• Lister J, Paisley S, Carroll C & Tappenden P () . PharmacoEconomics.
• Tappenden P, Hardiman O, Kwon S-H, Mon-Yee M, Galvin M & McDermott C () . PharmacoEconomics.
• Jin H, Tappenden P, Ling X, Robinson S & Byford S () . PLOS ONE, 18(9), e0291366-e0291366.
• Jin H, Tappenden P, MacCabe JH, Robinson S, McCrone P & Byford S () . The British Journal of Psychiatry, 1-6.
• Hind D, Tappenden P, Peters J & Kenjegalieva K () . Health Technology Assessment, 13(Suppl 2), 9-13.
• Wildman M, O'Cathain A, Maguire C, Arden M, Hutchings M, Bradley J, Walters S, Whelan P, Ainsworth J, Buchan I , Mandefield L et al () . Thorax.
• Wildman M, Hutchings M, Arden M, O'Cathain A, Drabble S, Walters SJ, Tappenden P, Beever D, Whelan P, Bradley J , Cantrill H et al () .
• Campbell F, Holmes M, Everson-Hock E, Davis S, Buckley Woods H, Anokye N, Tappenden P & Kaltenthaler E () . Health Technology Assessment, 19(60), 1-110.
• Harnan SE, Tappenden P, Essat M, Gomersall T, Minton J, Wong R, Pavord I, Everard M & Lawson R () . Health Technology Assessment, 19(82), 1-330.
• Cooper K, Tappenden P, Cantrell A & Ennis K () A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer. British Journal of Cancer.
• Wildman MJ, O’Cathain A, Hind D, Maguire C, Arden MA, Hutchings M, Bradley J, Walters SJ, Whelan P, Ainsworth J , Tappenden P et al () . Programme Grants for Applied Research, 9(11), 1-146.

Chapters

• Tappenden P (2014) , Encyclopedia of Health Economics (pp. 168-179). Elsevier

Conference proceedings papers

• Needham KJ, Tappenden P, Gillespie D & Whyte S (2023) Model-based Evaluations of the Cost-effectiveness of Interventions for Lung Cancer: A Systematic Review. JOURNAL OF THORACIC ONCOLOGY, Vol. 18(11) (pp S134-S134)
• Lister J, Paisley S, Tappenden P & Carroll C (2023) IDENTIFICATION OF HEALTH STATE UTILITY VALUES FOR HEALTH ECONOMIC MODELS: EMPIRICAL TESTING OF ALTERNATIVE SEARCH METHODS. VALUE IN HEALTH, Vol. 26(12) (pp S174-S175)
• Wheaton L, Poad H, Tappenden P & Bujkiewicz S (2023) BAYESIAN META-ANALYSIS OF DATA FROM TRIALS OF MIXED PATIENT POPULATIONS TO INFORM HEALTH ECONOMIC MODELS FOR PATIENTS HARBORING A PREDICTIVE BIOMARKER. VALUE IN HEALTH, Vol. 26(12) (pp S425-S425)
• Lister J, Paisley S, Tappenden P & Carroll C (2023) A SCOPING REVIEW OF HEALTH TECHNOLOGY ASSESSMENT AGENCY (HTA) AND HEALTH ECONOMIC (HE) MODELLING GUIDELINES FOR IDENTIFICATION OF HEALTH ECONOMIC MODEL INPUTS. VALUE IN HEALTH, Vol. 26(12) (pp S375-S375)
• Alshreef A, Latimer N, Tappenden P, McKane W, Hughes DA & Dixon S (2022) A METHODOLOGICAL FRAMEWORK TO ACCOUNT FOR THE IMPACT OF NON-ADHERENCE ON THE COST-EFFECTIVENESS OF CHRONIC MEDICATIONS. VALUE IN HEALTH, Vol. 25(7) (pp S520-S520)
• Alshreef A, Latimer N, Tappenden P, McKane W, Fotheringham J & Dixon S (2022) A CASE STUDY ASSESSING THE COST-EFFECTIVENESS OF MAINTENANCE IMMUNOSUPPRESSIVE THERAPY FOR KIDNEY TRANSPLANTATION IN ADULTS: ACCOUNTING FOR NON-ADHERENCE USING DATA FROM A RANDOMISED TRIAL AND THE REAL WORLD WITHIN A DECISION-ANALYTIC MODEL. VALUE IN HEALTH, Vol. 25(7) (pp S529-S529)
• Srivastava T, Latimer NR & Tappenden P (2020) ESTIMATION OF TRANSITION PROBABILITIES FOR STATE-TRANSITION MODELS: A REVIEW OF NICE APPRAISALS. VALUE IN HEALTH, Vol. 23 (pp S615-S616)
• Alshreef A, Latimer N, Tappenden P, McKane W, Wong R, Hughes D, Wailoo A, White I, Fotheringham J & Dixon S (2018) Adjusting the causal effects of treatments in the presence of patient non-adherence: a systematic review of methodological papers. European Society for Patient Adherence, Compliance and Persistence, Dublin, 29 November 2018 - 1 December 2018.
• Tappenden P, Wang Y, Burman J, Kazmi M, Saccardi R, Bermejo I, Harvey R, Badoglio M, Farge D, Sharrack B & Snowden J (2017) Evaluating the cost-effectiveness of autologous haematopoietic stem cell transplantation (aHSCT) versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison (MAIC). BONE MARROW TRANSPLANTATION, Vol. 52 (pp S41-S41)
• Kaltenthaler E, Carroll C, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M, Tappenden P & Woolacott N (2016) . Value in Health, Vol. 19(7) (pp A490-A490)
• Carroll C, Kaltenthaler E, Tappenden P, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M & Woolacott N (2016) . Value in Health, Vol. 19(7) (pp A468-A469)
• Goodall M, Tosh J, Alshreef A & Tappenden P (2016) . Value in Health, Vol. 19(7) (pp A366-A366)
• Harnan S, Essat M, Gomersall T, Tappenden P, Wong R, Lawson R, Pavord I & Everard M (2015) . Value in Health, Vol. 18(7) (pp A345-A345)
• Tappenden P, Harnan S, Uttley L, Mildred M, Taylor CJ, Brownlee K & Walshaw M (2013) . Value in Health, Vol. 16(7) (pp A372-A372)
• Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad E, Buyse M & Taylor R (2013) . VALUE IN HEALTH, Vol. 16(7) (pp A327-A327)
• Harnan SE, Uttley L, Cantrell A, Taylor CJ, Walshaw M, Brownlee K & Tappenden P (2013) . VALUE IN HEALTH, Vol. 16(7) (pp A367-A367)
• Kaltenthaler E, Rathbone J, Tappenden P, Bessey A & Cantrell A (2012) . VALUE IN HEALTH, Vol. 15(7) (pp A455-A455)
• Tappenden P, Brennan A, Chilcott J & Squires H (2011) . VALUE IN HEALTH, Vol. 14(7) (pp A469-A470)
• Tappenden P, Brennan A, Chilcott J & Squires H (2011) . VALUE IN HEALTH, Vol. 14(7) (pp A243-A243)
• Delea TE, Tappenden P, Sofrygin O, Karnon J, Amonkar M, Browning D, Rudge H & Walker M (2007) Cost-effectiveness (CE) of lapatinib plus capecitabine (L plus C) in women with ErbB2+(HER2+) metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the United Kingdom (UK) National Health Service (NHS) perspective. EJC SUPPLEMENTS, Vol. 5(4) (pp 225-225)

Scholarly editions

• Claxton K, Eggington S, Ginnelly L, Griffin S, McCabe C, Philips Z, Tappenden P & Wailoo A A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Health and Clinical Excellence.
• Tappenden P, Brazier J & Ratcliffe J Does the National Institute for Health and Clinical Excellence take account of factors such as uncertainty and equity as well as incremental cost-effectiveness in commissioning health care services? A binary choice experiment.

Posters

• Rathbone J, Kaltenthaler E, Tappenden P, Bessey A & Cantrell A Issues in the systematic review of drugs for rare diseases: A case study of Eculizumab for AHUS (2012).
• Harnan S, Essat M, Gomersall T, Tappenden P, Wong R, Lawson R, Pavord I & Everard M Exhaled nitric oxide for the diagnosis of asthma in children and adults: a systematic review.
• Kaltenthaler E, Tappenden P & Paisley S Reviewing the evidence used in cost effectiveness models in health technology assessment: a qualitative investigation of current concerns.
• Tappenden P, Brennan A, Chilcott J & Squires H Using Whole Disease Modelling to inform economic recommendations for the detection, diagnosis, treatment and followup of colorectal cancer.

Preprints

• Umemneku-Chikere CM, Wheaton L, Poad H, Ray D, Andrade IC, Khan S, Tappenden P, Abrams KR, Owen RK & Bujkiewicz S (2023) , arXiv.